AnaptysBio, Inc. manages royalty-focused financial collaborations tied to Jemperli with GSK and imsidolimab with Vanda. Following the completed separation of First Tracks Biotherapeutics, the company’s recurring updates center on royalty asset management, collaboration economics, contractual rights, stock repurchase activity, and governance changes.
News about ANAB also includes developments involving imsidolimab, a licensed antibody asset being developed by Vanda, and legal or contractual matters related to the Jemperli collaboration. Company announcements have additionally covered board and finance leadership appointments and the corporate transition from a biopharma operations business to a streamlined royalty management model.
Anaptys (NASDAQ: ANAB) announced a $100 million stock repurchase plan and a business update ahead of the planned spin-off of First Tracks Biotherapeutics (TRAX) targeted for April 20, 2026. Post-spin-off, Anaptys will manage royalty and financial collaborations for Jemperli and imsidolimab, operate with ~10 FTEsannualized expenses <$10M and initial net cash and investments of approximately $140–$145M.
The company appointed Susannah Gray to the board, engaged Piper Sandler as exclusive financial advisor, and anticipates paying down remaining non-recourse debt to Sagard by end of Q2 2027.
Anaptys (Nasdaq: ANAB) announced a planned Q2 2026 spin-off of its biopharma portfolio into a new public company, First Tracks Biotherapeutics (TRAX), while retaining a royalty-management company under the Anaptys name.
Key financials: year-end cash and investments of $311.6M, Q4 2025 net income of $49.6M, and full-year 2025 net loss of $13.2M. Jemperli sales reached $343M in Q4 2025, implying a ~$1.4B annualized run rate and potential >$390M annualized royalties to Anaptys at GSK peak guidance.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced FDA acceptance of its Biologics License Application for imsidolimab to treat Generalized Pustular Psoriasis (GPP), with a target action date of December 12, 2026.
Pivotal GEMINI-1/2 studies showed 53% achieving GPPPGA 0/1 at Week 4 versus 13% placebo; efficacy maintained during ~2-year monthly maintenance, with a favorable safety profile and low anti-drug antibodies.
Anaptys (Nasdaq: ANAB) announced that its CEO Daniel Faga and other executives will participate in multiple investor conferences in February–March 2026, including Guggenheim, Piper Sandler, TD Cowen, Barclays, UBS, and Leerink.
Live fireside chats and 1x1 meetings are scheduled; webcasts will be available on the company's investor website with replays for at least 30 days.
Summary not available.
Anaptys (Nasdaq: ANAB) announced that Daniel Faga, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET.
A live webcast will be available on the company's investor site at https://ir.anaptysbio.com/presentations-and-events, with a replay available for at least 30 days after the event.
Vanda Pharmaceuticals (Nasdaq: VNDA) submitted a Biologics License Application (BLA) to the FDA on Dec 15, 2025 for imsidolimab to treat generalized pustular psoriasis (GPP).
The BLA is supported by positive global Phase 3 GEMINI-1 and GEMINI-2 results: a single intravenous dose produced rapid clearance (clear or almost clear skin) with efficacy maintained during an approximately 2-year maintenance period with monthly dosing, and a favorable safety profile with no clinically meaningful safety signals reported. Vanda requested priority review, which could enable FDA action as early as mid-2026 if granted.
Anaptys (Nasdaq: ANAB) said CEO Daniel Faga and other executives will participate in multiple December investor conferences, including a fireside chat and 1x1 meetings at the Piper Sandler 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 1:30 PM ET and the Evercore 8th Annual Healthcare Conference in Coral Gables on Dec 3, 2025 at 7:55 AM ET.
Live webcasts of the fireside chats will be available on the company investor website and replays will be available for at least 30 days after each event.
Anaptys (Nasdaq: ANAB) announced an amended $100.0 million stock repurchase plan, in addition to $6.4 million remaining under the prior $75.0 million plan.
The company previously repurchased 3,443,188 shares, equal to 11.2% of shares outstanding before that repurchase program. Purchases may occur in open market transactions or under Rule 10b5-1/10b-18 programs.
Anaptys expects to end 2025 with approximately $300 million in cash, cash equivalents and investments, which includes an anticipated one-time $75 million commercial sales milestone from GSK tied to Jemperli reaching $1 billion in worldwide net sales. The repurchase plan expires March 31, 2026 and may be suspended or discontinued at any time; it does not obligate any repurchases.
Summary not available.